XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released an update on its Rotigotine transdermal (“TDS”) patch. The patch is based on the TDS platform technology developed by the company’s wholly owned German subsidiary, Vektor Pharma TF GmbH. The company noted that it had completed a human cadaver skin permeation study earlier this month; the two-week, open-label, randomized, crossover, two-period, two-sequence, single-dose study was designed to evaluate the relative bioavailability and absorption of its Rotigotine TDS product compared to the name brand product. XPhyto noted that it is working toward commercialization of the proprietary treatment as Vektor focuses on formula optimization. According to the announcement, study results were positive with the company’s new formulas demonstrating absorption within the generic drug formulation target range (plus or minus 20%) in all three cadaver skin samples. The company now plans to reproduce the human cadaver skin permeation study before moving forward to finalize the formula and identifying the manufacturing process. XPhyto noted that, pending positive results from the next study, it anticipates filing for regulatory approval; the company will focus its efforts in the European Union initially.
To view the full press release, visit https://ibn.fm/8s3vy
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug formulation, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological conditions. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany. The company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
